Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ULK1 | O75385 | 4/20 | 0.59 |
| ▸ | AAK1 | Q2M2I8 | 4/20 | 0.53 |
| ▸ | MAP2K4 | P45985 | 1/20 | 0.52 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.50 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.48 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.48 |
| ▸ | ITK | Q08881 | 1/20 | 0.47 |
| ▸ | TTK | P33981 | 2/20 | 0.47 |
| ▸ | MAPK8 | P45983 | 2/20 | 0.47 |
| ▸ | AURKA | O14965 | 3/20 | 0.46 |
| ▸ | MAP2K7 | O14733 | 1/20 | 0.45 |
| ▸ | GAK | O14976 | 1/20 | 0.45 |
| ▸ | STK16 | O75716 | 1/20 | 0.45 |
| ▸ | BMP2K | Q9NSY1 | 1/20 | 0.45 |
| ▸ | IP6K1 | Q92551 | 1/20 | 0.45 |
| ▸ | IP6K3 | Q96PC2 | 1/20 | 0.45 |
| ▸ | IP6K2 | Q9UHH9 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5381639 | 0.95 | AAK1 (0.59) | ULK1AAK1MAP2K4PDPK1CSNK2A1 | |
| SCHEMBL5382027 | 0.87 | MAPK10 (0.58) | ULK1AAK1MAP2K4PDPK1CSNK2A1 | |
| SCHEMBL2865036 | 0.84 | PDPK1 (0.65) | ULK1AAK1PDPK1CSNK2A1ITK | |
| SCHEMBL5377947 | 0.83 | MAP2K4 (0.63) | MAP2K4TTKMAPK8AURKAMAP2K7 | |
| SCHEMBL12073910 | 0.82 | TTK (0.65) | MAP2K4ITKTTKMAPK8AURKA | |
| SCHEMBL5785886 | 0.81 | AURKA (0.66) | MAP2K4ITKTTKMAPK8AURKA | |
| SCHEMBL5374309 | 0.79 | ROCK2 (0.49) | ULK1MAP2K4TTKMAPK8AURKA | |
| SCHEMBL5374305 | 0.79 | MAP2K4 (0.46) | ULK1MAP2K4TTKMAPK8AURKA | |
| SCHEMBL6545151 | 0.78 | TTK (0.49) | ULK1AAK1PDPK1CSNK2A1ITK | |
| SCHEMBL6793415 | 0.78 | PARP1 (0.60) | ULK1ROCK1CSNK2A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7220771-B2 | Methods of using indazole derivatives as JNK inhibitors | SIGNAL PHARMACEUTICALS, LLC (US) | 2007-05-22 | — | — | US | disclosed |
| US-7220771-B2 | Methods of using indazole derivatives as JNK inhibitors | SIGNAL PHARMACEUTICALS, LLC (US) | 2007-05-22 | — | — | US | disclosed |
| US-7211594-B2 | Indazole compounds and compositions thereof as JNK inhibitors and for the treatment of diseases associated therewith | SIGNAL PHARMACEUTICALS, LLC (US) | 2007-05-01 | — | — | US | disclosed |
| US-7211594-B2 | Indazole compounds and compositions thereof as JNK inhibitors and for the treatment of diseases associated therewith | SIGNAL PHARMACEUTICALS, LLC (US) | 2007-05-01 | — | — | US | disclosed |
| US-7208513-B2 | Indazole compounds and compositions thereof as JNK inhibitors and for the treatment of diseases associated therewith | SIGNAL PHARMACEUTICALS, LLC (US) | 2007-04-24 | — | — | US | disclosed |
| US-7208513-B2 | Indazole compounds and compositions thereof as JNK inhibitors and for the treatment of diseases associated therewith | SIGNAL PHARMACEUTICALS, LLC (US) | 2007-04-24 | — | — | US | disclosed |
| US-20070060616-A1 | Methods for treating, preventing and managing chronic lymphocytic leukemia with indazole compounds | SIGNAL PHARMACEUTICALS, LLC | 2007-03-15 | — | — | US | disclosed |
| US-20070060616-A1 | Methods for treating, preventing and managing chronic lymphocytic leukemia with indazole compounds | SIGNAL PHARMACEUTICALS, LLC | 2007-03-15 | — | — | US | disclosed |
| US-20050009876-A1 | Indazole compounds, compositions thereof and methods of treatment therewith | SIGNAL PHARMACEUTICALS, LLC | 2005-01-13 | — | — | US | disclosed |
| US-20050009876-A1 | Indazole compounds, compositions thereof and methods of treatment therewith | SIGNAL PHARMACEUTICALS, LLC | 2005-01-13 | — | — | US | disclosed |
| US-20040127536-A1 | Methods for treating an inflammatory condition or inhibiting JNK | SIGNAL PHARMACEUTICALS, LLC | 2004-07-01 | — | — | US | disclosed |
| US-20040127536-A1 | Methods for treating an inflammatory condition or inhibiting JNK | SIGNAL PHARMACEUTICALS, LLC | 2004-07-01 | — | — | US | disclosed |
| WO-2002010137-A9 | INDAZOLE DERIVATIVES AS JNK INHIBITORS | SIGNAL PHARM INC (US) | 2003-02-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040127536-A1 | Methods for treating an inflammatory condition or inhibiting JNK | MAPK1, MAP3K1, MAPKAPK2 | ULK1 179/4885AAK1 150/4885MAP2K4 130/4885 |
| US-20070060616-A1 | Methods for treating, preventing and managing chronic lymphocytic leukemia with indazole compounds | BCL9, MCL1, INMT | ULK1 2079/4885AAK1 3487/4885MAP2K4 3021/4885 |
| US-20050009876-A1 | Indazole compounds, compositions thereof and methods of treatment therewith | GPR119, JAK3, IGF1R | ULK1 176/4885AAK1 652/4885MAP2K4 385/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.